Colorado Springs, Colorado -- Biotechnology company Pyxant Labs has received $440,000 in new equity venture capital investment, according to an SEC regulatory filing.
Pyxant is a contract research laboratory that focuses on GLP bioanalytical chemistry support for life sciences companies.
Investors in the financing were not disclosed and neither was ow the company intends to use the proceeds.
A total of 6 investors participated in the offering.
Pyxant is still seeking $210,000 in additional equity investment, according to the filing.